Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07315113 · ClinicalTrials.gov registry record · Phase 1
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients, sponsored by Nuvectis Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT07315113: Recruiting Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients, sponsored by Nuvectis Pharma.
NCT07315113 is a Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients that is actively recruiting participants, run by Nuvectis Pharma. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07315113, a Phase 1 study of EGFR Mutation Positive Non-small Cell Lung Cancer and EGFR Mutated Non-small Cell Lung Cancer Patients, is actively recruiting participants, sponsored by Nuvectis Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG NXP900
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
Texas
- NEXT Houston - Houston
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-12-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT07315113 shows while recruiting
NCT07315113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with EGFR Mutation Positive Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT07315113 reports a single indexed study location in Massachusetts, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT07315113 about?
NCT07315113 is a clinical study titled "Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer". This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
What is the current status of trial NCT07315113?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-12-18. Estimated completion is 2027-06.
What conditions does trial NCT07315113 study?
This clinical trial studies the following conditions: EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients.
What interventions are being tested in trial NCT07315113?
The interventions under investigation include: Osimertinib (DRUG), NXP900 (DRUG).
Who is sponsoring clinical trial NCT07315113?
This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07315113 being conducted?
This trial has 3 study locations across Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07315113's enrollment target sits among peer trials
18 1721st of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI